A New Immunotherapy Combination for Metastatic Pancreatic Cancer
Researchers are looking at a combination of two types of monoclonal antibodies to treat advanced pancreatic cancer.
Researching More Second-Line Options for Pancreatic Cancer
Dr. Allyson Ocean explains the concept behind a novel second-line treatment being tested for metatstatic pancreatic cancer.
New Trial to Find Biomarkers to Guide Treatment
Drs. Jennifer Knox and Elizabeth Jaffee lead the PASS-01 trial using biomarkers and other measures to choose individualized treatment.
Multi-Site Precision Promise Study Opens
Dr. Vincent Picozzi explains how Precision Promise clinical trial will use a personalized approach for pancreatic cancer patients.
NALIRIFOX Shows Promise in Early Studies
Dr. Zev Wainberg describes the new combination NALIRIFOX, being tested in the NAPOLI-3 clinical trial for advanced pancreatic cancer patients.
Slowing the Spread of Advanced Pancreatic Cancer
Researchers are testing a kinase inhibitor that is used to treat lung diseases, including a type of lung cancer, against pancreatic cancer.
GENERATE Trial Expands Eligibility
Dr. Sapna Syngal explains the expanded eligibility standards for the GENERATE Study for genetic testing of pancreatic cancer patients and relatives.
COMBATing Pancreatic Cancer
Dr. Manuel Hidalgo explains the COMBAT trial, which combines immunotherapy, a checkpoint inhibitor, and chemotherapy to attack pancreatic cancer.
A New Drug to Target Cancer Cell Enzymes
This trial remains active but is no longer recruiting participants. In patients with metastatic pancreatic cancer, researchers are comparing FOLFIRINOX, the standard treatment, with FOLFIRINOX plus CPI-613, a new drug that works on enzymes involved in cancer cell energy metabolism. Target: Enzymes Mitochondria are components within a cell that are responsible for generating the energy…
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.